| HOME >> BIOLOGY >> TECHNOLOGY |
For the nine months ended December 31, 2007, net sales of $9.7 million increased 71% from $5.7 million for the same period in the prior year. Excluding the translation impact of fluctuations in foreign currency exchange rates, sales increased by approximately 64%.
For the nine months ended December 31, 2007, sales to customers in the U.S. increased to $5.5 million, compared to $752,000 in the same nine-month period last year. Sales to customers outside the U.S. for the nine months ended December 31, 2007 were $5.5 million, representing a 12% increase, compared to $4.9 million in the same nine-month period last year. Excluding the translation impact of fluctuations in foreign currency exchange rates, sales to customers outside of the U.S. increased by approximately 4%.
Non-GAAP operating loss, which excludes non cash charges attributed to
SFAS 123 (R) stock options, and depreciation and amortization expenses, as
set forth below and reconciled to GAAP operating loss, declined to
approximately $466,000 and $1.5 million for the three and nine months ended
December 31, 2007 respectively, from approximately $820,000 and $3.3
million for the respective year ago periods. Included in the three and nine
months ended December 31, 2007 is a $214,000 charge attributed to the cost
for exiting the lease of the manufacturing facility in Eindhoven, The
Netherlands and severance pay. The decline in non-GAAP operating loss is
attributed primaril
'/>"/>
| SOURCE Uroplasty, Inc. Copyright©2008 PR Newswire. All rights reserved |